VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Melanoma MORE >>

The FDA approved several indications throughout the month of April 2018. A number of drugs were granted priority review and Fast Track designation. The FDA also halted all clinical trials using tazemetostat as treatment, and new initiatives were introduced to help ease the development of genetic and genomic-based tests. Check out our list of all FDA happenings from April 2018.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.